RNAimmune
PrivateLast Round
Series A
Mar 29, 2022
Total Funding Raised
$39.35M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
RNAimmune is a biotechnology company specializing in mRNA-based therapeutics and vaccines aimed at addressing cancer, infectious, and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RNAimmune Comparables
Compare RNAimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Replicate Bioscience | 84% | |
| Providence Therapeutics | 82% | |
| Kernalbio | 81% | |
RNAimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 29, 2022 | ||||
| Seed | Apr 21, 2021 | ||||
| Angel | Aug 24, 2020 |
RNAimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Terra Magnum Capital Partners | Angel |
| Rotating Boulder Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 64% MoM.
- Mar 29, 2022
$27M round led by Sirnaomics.
RNAimmune Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about RNAimmune's valuation, stock price, and market status.